9. Omics for cell therapies
by Eagle Genomics Ltd. on Apr 12, 2012
- 656 views
This is the ninth presentation from Eagle Genomics 2nd symposium held on 29th March 2012. Presented by Alex Gutteridge from Pfizer Neusentis....
This is the ninth presentation from Eagle Genomics 2nd symposium held on 29th March 2012. Presented by Alex Gutteridge from Pfizer Neusentis.
"The next generation of cell-based regenerative medicine therapies will require next generation approaches to questions of cell identity: How do we define and characterise different cell types generated in-vivo and in-vitro, how can we drive one cell type into another and how can we track cells once they enter the patient? The transcriptome, proteome, secretome,epigenome and genome, as well as phenomic high throughput imaging data, all have important roles to play in addressing these questions. I will discuss the challenges we face in terms of gathering, storing and disseminating these data in the research, clinical and production stages of our therapies.I will argue that establishing standards for defining cell identity is a fundamentally collaborative endeavour and discuss a number of ongoing collaborations we have around this area."
- Total Views
- Views on SlideShare
- Embed Views